首页> 外文期刊>Japanese Journal of Cancer Research >Receptor for hyaluronan-mediated motility and CD44 expressions in colon cancer assessed by quantitative analysis using real-time reverse transcriptase-polymerase chain reaction.
【24h】

Receptor for hyaluronan-mediated motility and CD44 expressions in colon cancer assessed by quantitative analysis using real-time reverse transcriptase-polymerase chain reaction.

机译:透明质酸介导的运动和CD44表达在结肠癌中的受体通过使用实时逆转录酶-聚合酶链反应的定量分析进行评估。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Receptor for hyaluronan (HA)-mediated motility (RHAMM) is a receptor for HA-mediated motility and its expression is correlated with malignancy of ras-transformed cells in that binding of HA to this receptor activates their migratory ability. CD44, a cell surface receptor for HA is also implicated in metastatic behavior of some cancer cells. In this study we examined the relationships of cancer progression with mRNA levels of RHAMM, CD44 (all forms), and exon 6 of CD44 using the real-time reverse transcriptase-polymerase chain reaction method in specimens of colon cancers at different diagnostic stages from 30 patients. Increased mRNA levels of RHAMM were observed in 29 specimens (97%), CD44s (all forms) in 21 specimens (70%), and its exon 6 in 19 specimens (63%) in comparison with those in the corresponding noncancerous tissue specimens. A statistically significant correlation between RHAMM expression and cancerous specimens at any of Dukes' stages A, B, and C was found, and the overexpression of CD44 mRNAs was confirmed in specimens at Dukes' stage C. Thus, our present study for the first time suggests that RHAMM expression may be a clinically useful indicator of colon cancer.
机译:透明质酸(HA)介导的运动(RHAMM)的受体是HA介导的运动的受体,其表达与ras转化细胞的恶性相关,因为HA与该受体的结合激活了其迁移能力。 CD44,HA的细胞表面受体,也与某些癌细胞的转移行为有关。在这项研究中,我们使用实时逆转录-聚合酶链反应方法研究了结肠癌标本中不同诊断阶段(从30岁开始)的癌症进展与RHAMM,CD44(所有形式)和CD44外显子6 mRNA水平之间的关系。耐心。与相应的非癌性组织标本相比,在29个标本(97%),21个标本(70%)中的CD44s(所有形式)和19个标本(63%)中其外显子6的RHAMM mRNA水平增加。发现RHAMM表达与Dukes的A,B和C期中的癌标本之间存在统计学上的显着相关性,并且在Dukes的C期标本中证实了CD44 mRNA的过表达。因此,本研究是首次提示RHAMM表达可能是结肠癌的临床有用指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号